A pentapeptide growth hormone secretagogue prized for its exceptional selectivity — it stimulates GH release without the cortisol, prolactin, or appetite side effects that complicate research with older GHRPs.
Ipamorelin is a synthetic five-amino-acid peptide (pentapeptide) that acts as a Growth Hormone Releasing Peptide (GHRP) — it stimulates the pituitary gland to release growth hormone by acting on ghrelin receptors (the GHS-R1a receptor). It was developed by Novo Nordisk in the 1990s as a research tool and later studied as a pharmaceutical candidate.
What made Ipamorelin scientifically interesting was what it didn't do as much as what it did. Earlier GHRPs like GHRP-6 and GHRP-2 also stimulate GH release but come with significant side effects in research models: they also elevate cortisol, prolactin, and cause pronounced appetite stimulation. Ipamorelin was engineered to be highly selective — it stimulates GH release with minimal off-target receptor activation, making it a cleaner research tool for studying GH secretion in isolation.
This selectivity has made Ipamorelin the preferred GHRP for many research models where the goal is to study GH and IGF-1 effects without confounding variables from cortisol or prolactin changes.
📡 Weekly peptide research updates — regulatory updates, new compound profiles, COA alerts.
⚠️ FDA PCAC: -- days leftNo spam. Unsubscribe anytime. 7 peptides under review — see what's at stake →
7 free research tools built around exactly this kind of compound data. No paywall, no credit card.
Ipamorelin binds to the ghrelin receptor (GHS-R1a), which is expressed on somatotroph cells in the anterior pituitary. This receptor was first identified as the receptor for ghrelin — the "hunger hormone" — but it turns out ghrelin receptor activation also potently stimulates GH release. Ipamorelin mimics this ghrelin-receptor activation specifically for the GH release effect, while being engineered to minimize the appetite-stimulating and cortisol-releasing effects that natural ghrelin and older GHRPs produce.
The result is a GH pulse that looks similar to a natural pituitary GH pulse — short, pronounced, and self-limiting — rather than a sustained elevation.
Think of the pituitary as a drummer who releases GH in rhythmic beats. Natural pituitary signaling creates a specific beat pattern — big pulses during sleep, smaller pulses through the day. Ipamorelin is like a very precise drum stick that triggers exactly one clean beat on the GH drum without accidentally hitting the cortisol cymbal or the prolactin snare. Older GHRPs were like hitting all the drums at once.
Research Disclaimer: The following reflects published clinical and preclinical research and is not medical advice. Consult a licensed healthcare provider before making any health decisions.
Ipamorelin was developed by Novo Nordisk and has been studied in phase I/II human trials for GI motility disorders in addition to GH research. Published pharmacokinetic and GH-response data from these trials provides concrete clinical reference points.
Ipamorelin in research settings is reconstituted from lyophilized powder using bacteriostatic water. The short half-life (approximately 2 hours in plasma) means solution stability requirements are less critical than compounds requiring longer exposures. Lyophilized stability documented at −20°C for extended storage. Reconstituted solution stability at 4°C is cited in standard research protocols as adequate for short-term use (days).
GI motility clinical trials used three-times-daily IV administration (around meals). Research protocols for GH axis studies have generally used 1–3 SC injections per day. The nocturnal GH pulse timing rationale (used for Sermorelin) also applies — bedtime or overnight dosing aligns with peak somatotroph sensitivity to secretagogue stimulation. No published randomized comparison of dosing timing exists for ipamorelin specifically.
Key References: Raun K et al. (1998). Ipamorelin — selective GH secretagogue. Eur J Endocrinol. · Svensson J et al. (2000). Ipamorelin bone density in rodents. Growth Horm IGF Res. · Poitras P et al. (2009). Ipamorelin postoperative ileus trial. J Gastrointest Surg.
Ipamorelin's selectivity was a deliberate engineering achievement, not an accident. Researchers at Novo Nordisk systematically modified the GHRP-2 peptide structure to eliminate off-target receptor activation while preserving GH-releasing potency — a nice example of rational peptide drug design.
The ghrelin receptor that Ipamorelin activates was discovered after ipamorelin was already in development — scientists identified a receptor whose ligand turned out to be ghrelin. Ipamorelin was part of the research toolkit that helped characterize this receptor system.
Research in animal models has shown Ipamorelin's GH-releasing effect is amplified roughly 3–5x when combined with a GHRH analog like CJC-1295 — demonstrating the synergistic interplay between the two GH-stimulating pathways.
Every batch of Ipamorelin with full Certificate of Analysis documentation. Third-party HPLC verification, mass spectrometry confirmation, and sterility testing results are included with each batch.